Taysha Gene Therapies, Inc.
SEC CIK 1806310 · TSHA · last insider filing 2026-06-02
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Donenberg Phillip B. | Director | filed 2020 - 2026 |
| Stalfort Sean | Director | filed 2023 - 2026 |
| Sepp-Lorenzino Laura | Director | filed 2020 - 2026 |
| Long Alison S | Director | filed 2023 - 2026 |
| Nagendran Sukumar | Director · President and Head of R&D | filed 2020 - 2026 |
| Nolan Sean P. | Director · Chief Executive Officer | filed 2020 - 2026 |
| Manning Paul B | Director | filed 2020 - 2025 |
| Session R.A. II | Director · President and CEO | filed 2020 - 2023 |
| Reape Kathleen | Director | filed 2020 - 2023 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Alam Kamran | Chief Financial Officer | filed 2020 - 2026 |
| Prasad Suyash | CMO and Head of R&D | filed 2020 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.